Andarix

Vixilide®, a novel, best-in-class therapy for lung, neuroendocrine, and other cancers based on the proprietary somatostatin peptide conjugate P2045. Treatment with Vixilide represents a personalized approach, as between 80-90% of these patients are known to overexpress the target, somatostatin receptor 2, and the most appropriate patients having these tumors can be selected prior to therapy by imaging. This next generation approach rapidly kills cancer cells and spares healthy tissue.